Dexrazoxane	dexrazoxane	O	O	OTHERS	I
protects	protects	O	O	O	O
against	against	O	O	O	O
myelosuppression	myelosuppression	O	DISEASE	OTHERS	I
from	from	O	O	O	O
the	the	O	O	O	O
DNA	dna	O	O	O	O
cleavage-enhancing	cleavage-enhancing	O	O	O	O
drugs	drugs	O	O	O	O
etoposide	etoposide	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
daunorubicin	daunorubicin	CHEMICALS	O	OTHERS	I
but	but	O	O	O	O
not	not	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

PURPOSE	purpose	O	O	O	O
:	:	O	O	O	O
The	the	O	O	O	O
anthracyclines	anthracyclines	O	O	OTHERS	I
daunorubicin	daunorubicin	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
the	the	O	O	O	O
epipodophyllotoxin	epipodophyllotoxin	O	O	OTHERS	I
etoposide	etoposide	CHEMICALS	O	OTHERS	I
are	are	O	O	O	O
potent	potent	O	O	O	O
DNA	dna	O	O	O	O
cleavage-enhancing	cleavage-enhancing	O	O	O	O
drugs	drugs	O	O	O	O
that	that	O	O	O	O
are	are	O	O	O	O
widely	widely	O	O	O	O
used	used	O	O	O	O
in	in	O	O	O	O
clinical	clinical	O	O	O	O
oncology	oncology	O	O	O	O
;	;	O	O	O	O
however	however	O	O	O	O
,	,	O	O	O	O
myelosuppression	myelosuppression	O	DISEASE	OTHERS	I
and	and	O	O	O	O
cardiac	cardiac	O	DISEASE	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
limit	limit	O	O	O	O
their	their	O	O	O	O
use	use	O	O	O	O
.	.	O	O	O	O

Dexrazoxane	dexrazoxane	O	O	OTHERS	I
(	(	O	O	O	O
ICRF-187	icrf-187	O	O	OTHERS	I
)	)	O	O	O	O
is	is	O	O	O	O
recommended	recommended	O	O	O	O
for	for	O	O	O	O
protection	protection	O	O	O	O
against	against	O	O	O	O
anthracycline-induced	anthracycline-induced	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

EXPERIMENTAL	experimental	O	O	O	O
DESIGN	design	O	O	O	O
:	:	O	O	O	O
Because	because	O	O	O	O
of	of	O	O	O	O
their	their	O	O	O	O
widespread	widespread	O	O	O	O
use	use	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
hematologic	hematologic	O	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
following	following	O	O	O	O
coadministration	coadministration	O	O	O	O
of	of	O	O	O	O
dexrazoxane	dexrazoxane	O	O	OTHERS	I
and	and	O	O	O	O
these	these	O	O	O	O
three	three	O	O	O	O
structurally	structurally	O	O	O	O
different	different	O	O	O	O
DNA	dna	O	O	O	O
cleavage	cleavage	O	O	O	O
enhancers	enhancers	O	O	O	O
was	was	O	O	O	O
investigated	investigated	O	O	O	O
:	:	O	O	O	O
Sensitivity	sensitivity	O	O	O	O
of	of	O	O	O	O
human	human	O	O	O	O
and	and	O	O	O	O
murine	murine	O	O	O	O
blood	blood	O	O	O	O
progenitor	progenitor	O	O	O	O
cells	cells	O	O	O	O
to	to	O	O	O	O
etoposide	etoposide	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
daunorubicin	daunorubicin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
+	+	O	O	O	O
/-	/-	O	O	O	O
dexrazoxane	dexrazoxane	O	O	OTHERS	I
was	was	O	O	O	O
determined	determined	O	O	O	O
in	in	O	O	O	O
granulocyte-macrophage	granulocyte-macrophage	O	O	O	O
colony	colony	O	O	O	O
forming	forming	O	O	O	O
assays	assays	O	O	O	O
.	.	O	O	O	O

Likewise	likewise	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
vivo	vivo	O	O	O	O
,	,	O	O	O	O
B6D2F1	b6d2f1	O	O	O	O
mice	mice	O	O	O	O
were	were	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
etoposide	etoposide	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
daunorubicin	daunorubicin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
with	with	O	O	O	O
or	or	O	O	O	O
without	without	O	O	O	O
dexrazoxane	dexrazoxane	O	O	OTHERS	I
over	over	O	O	O	O
a	a	O	O	O	O
wide	wide	O	O	O	O
range	range	O	O	O	O
of	of	O	O	O	O
doses	doses	O	O	O	O
:	:	O	O	O	O
posttreatment	posttreatment	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
full	full	O	O	O	O
hematologic	hematologic	O	O	O	O
evaluation	evaluation	O	O	O	O
was	was	O	O	O	O
done	done	O	O	O	O
.	.	O	O	O	O

RESULTS	results	O	O	O	O
:	:	O	O	O	O
Nontoxic	nontoxic	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
dexrazoxane	dexrazoxane	O	O	OTHERS	I
reduced	reduced	O	O	O	O
myelosuppression	myelosuppression	O	DISEASE	OTHERS	I
and	and	O	O	O	O
weight	weight	O	DISEASE	OTHERS	I
loss	loss	O	DISEASE	OTHERS	I
from	from	O	O	O	O
daunorubicin	daunorubicin	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
etoposide	etoposide	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
mice	mice	O	O	O	O
and	and	O	O	O	O
antagonized	antagonized	O	O	O	O
their	their	O	O	O	O
antiproliferative	antiproliferative	O	O	O	O
effects	effects	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
colony	colony	O	O	O	O
assay	assay	O	O	O	O
;	;	O	O	O	O
however	however	O	O	O	O
,	,	O	O	O	O
dexrazoxane	dexrazoxane	O	O	OTHERS	I
neither	neither	O	O	O	O
reduced	reduced	O	O	O	O
myelosuppression	myelosuppression	O	DISEASE	OTHERS	I
,	,	O	O	O	O
weight	weight	O	DISEASE	OTHERS	I
loss	loss	O	DISEASE	OTHERS	I
,	,	O	O	O	O
nor	nor	O	O	O	O
the	the	O	O	O	O
in	in	O	O	O	O
vitro	vitro	O	O	O	O
cytotoxicity	cytotoxicity	O	O	OTHERS	I
from	from	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

CONCLUSION	conclusion	O	O	O	O
:	:	O	O	O	O
Although	although	O	O	O	O
our	our	O	O	O	O
findings	findings	O	O	O	O
support	support	O	O	O	O
the	the	O	O	O	O
observation	observation	O	O	O	O
that	that	O	O	O	O
dexrazoxane	dexrazoxane	O	O	OTHERS	I
reduces	reduces	O	O	O	O
neither	neither	O	O	O	O
hematologic	hematologic	O	O	O	O
activity	activity	O	O	O	O
nor	nor	O	O	O	O
antitumor	antitumor	O	O	O	O
activity	activity	O	O	O	O
from	from	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
clinically	clinically	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
potent	potent	O	O	O	O
antagonism	antagonism	O	O	O	O
of	of	O	O	O	O
daunorubicin	daunorubicin	CHEMICALS	O	OTHERS	I
activity	activity	O	O	O	O
raises	raises	O	O	O	O
concern	concern	O	O	O	O
;	;	O	O	O	O
a	a	O	O	O	O
possible	possible	O	O	O	O
interference	interference	O	O	O	O
with	with	O	O	O	O
anticancer	anticancer	O	O	O	O
efficacy	efficacy	O	O	O	O
certainly	certainly	O	O	O	O
would	would	O	O	O	O
call	call	O	O	O	O
for	for	O	O	O	O
renewed	renewed	O	O	O	O
attention	attention	O	O	O	O
.	.	O	O	O	O

Our	our	O	O	O	O
data	data	O	O	O	O
also	also	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
significant	significant	O	O	O	O
etoposide	etoposide	CHEMICALS	O	OTHERS	I
dose	dose	O	O	O	O
escalation	escalation	O	O	O	O
is	is	O	O	O	O
perhaps	perhaps	O	O	O	O
possible	possible	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
dexrazoxane	dexrazoxane	O	O	OTHERS	I
.	.	O	O	O	O

Clinical	clinical	O	O	O	O
trials	trials	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
brain	brain	O	O	O	O
metastases	metastases	O	O	OTHERS	I
combining	combining	O	O	O	O
dexrazoxane	dexrazoxane	O	O	OTHERS	I
and	and	O	O	O	O
high	high	O	O	O	O
doses	doses	O	O	O	O
of	of	O	O	O	O
etoposide	etoposide	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
ongoing	ongoing	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
aim	aim	O	O	O	O
of	of	O	O	O	O
improving	improving	O	O	O	O
efficacy	efficacy	O	O	O	O
without	without	O	O	O	O
aggravating	aggravating	O	O	O	O
hematologic	hematologic	O	O	OTHERS	I
toxicity	toxicity	O	DISEASE	OTHERS	I
.	.	O	O	O	O

If	if	O	O	O	O
successful	successful	O	O	O	O
,	,	O	O	O	O
this	this	O	O	O	O
represents	represents	O	O	O	O
an	an	O	O	O	O
exciting	exciting	O	O	O	O
mechanism	mechanism	O	O	O	O
for	for	O	O	O	O
pharmacologic	pharmacologic	O	O	O	O
regulation	regulation	O	O	O	O
of	of	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
from	from	O	O	O	O
cytotoxic	cytotoxic	O	O	O	O
chemotherapy	chemotherapy	O	O	O	O
.	.	O	O	O	O

